Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

‘Sinopharm, J&J, Sputnik Vaccines Are Weaker Against Omicron In New Study’ -Recent Bloomberg Article

https://www.bloomberg.com/news/articles/2021-12-17/sinopharm-j-j-sputnik-shots-weaken-against-omicron-study-sees
byBenzinga Newsdesk
December 17, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

https://www.bloomberg.com/news/articles/2021-12-17/sinopharm-j-j-sputnik-shots-weaken-against-omicron-study-sees

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AstraZeneca and Daiichi Sankyo Announced ENHERTU Met the Primary Endpoint of Progression-free Survival in Patients With Hr-positive Disease, Reducing the Risk of Disease Progression or Death by 49% Vs. Chemotherapy in Data Presented at ASCO

By Charles Gross
June 5, 8:39 AM
Detailed positive results from the pivotal DESTINY-Breast04 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated superior and clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously treated patients with HER2-low (immunohistochemistry (IHC) 1+ or IHC 2+/in-situ hybridization (ISH)-negative) unresectable and/or metastatic breast c

AZN